about
Efficient and biologically relevant consensus strategy for Parkinson's disease gene prioritization.New halogenated 3-phenylcoumarins as potent and selective MAO-B inhibitorsLigands and therapeutic perspectives of adenosine A(2A) receptorsChromone 3-phenylcarboxamides as potent and selective MAO-B inhibitorsNatural/random protein classification models based on star network topological indices.Synthesis and analysis of aminochromes by HPLC-photodiode array. Adrenochrome evaluation in rat blood.3D-MEDNEs: an alternative "in silico" technique for chemical research in toxicology. 2. quantitative proteome-toxicity relationships (QPTR) based on mass spectrum spiral entropy.Desirability-based multiobjective optimization for global QSAR studies: application to the design of novel NSAIDs with improved analgesic, antiinflammatory, and ulcerogenic profiles.Desirability-based methods of multiobjective optimization and ranking for global QSAR studies. Filtering safe and potent drug candidates from combinatorial libraries.Multidimensional drug design: simultaneous analysis of binding and relative efficacy profiles of N(6)-substituted-4'-thioadenosines A3 adenosine receptor agonists.Discovery of novel A3 adenosine receptor ligands based on chromone scaffold.Phenolic acid derivatives with potential anticancer properties--a structure-activity relationship study. Part 1: methyl, propyl and octyl esters of caffeic and gallic acids.Chromone: a valid scaffold in medicinal chemistry.Synthesis and cytotoxic profile of 3,4-methylenedioxymethamphetamine ("ecstasy") and its metabolites on undifferentiated PC12 cells: A putative structure-toxicity relationship.Electrochemical and spectroscopic characterisation of amphetamine-like drugs: application to the screening of 3,4-methylenedioxymethamphetamine (MDMA) and its synthetic precursors.The crystal structures of four N-(4-halophen-yl)-4-oxo-4H-chromene-3-carboxamides.New insights in the discovery of novel h-MAO-B inhibitors: structural characterization of a series of N-phenyl-4-oxo-4H-chromene-3-carboxamide derivativesBioactive Coumarins from Marine Sources: Origin, Structural Features and Pharmacological Properties.Crystal structures of two 6-(2-hy-droxy-benzo-yl)-5H-thia-zolo[3,2-a]pyrimidin-5-ones.Furocoumarins in medicinal chemistry. Synthesis, natural occurrence and biological activity.Prioritizing Hits with Appropriate Trade-Offs Between HIV-1 Reverse Transcriptase Inhibitory Efficacy and MT4 Blood Cells Toxicity Through Desirability-Based Multiobjective Optimization and Ranking.Simple coumarins and analogues in medicinal chemistry: occurrence, synthesis and biological activity.Chemoinformatics Profiling of the Chromone Nucleus as a MAO-B/A2AAR Dual Binding Scaffold.A comparison of the structures of some 2- and 3-substituted chromone derivatives: a structural study on the importance of the secondary carboxamide backbone for the inhibitory activity of MAO-B.Crystal structures of ethyl 6-(4-methyl-phen-yl)-4-oxo-4H-chromene-2-carboxyl-ate and ethyl 6-(4-fluoro-phen-yl)-4-oxo-4H-chromene-2-carboxyl-ate.New insights on the anticancer properties of dietary polyphenols.Crystal structures of five 6-mercaptopurine derivatives.Voltammetric insights in the transfer of ionizable drugs across biomimetic membranes: recent achievements.Crystal structures of three 3,4,5-tri-meth-oxy-benzamide-based derivativesLong-Term Treatment with Low Doses of Methamphetamine Promotes Neuronal Differentiation and Strengthens Long-Term Potentiation of Glutamatergic Synapses onto Dentate Granule Neurons.6-Methyl-2-oxo-N-(quinolin-6-yl)-2H-chromene-3-carboxamide: crystal structure and Hirshfeld surface analysis.Crystal structures of three 6-substituted coumarin-3-carboxamide derivatives.Variable delay-to-signal: a fast paradigm for assessment of aspects of impulsivity in ratsComputational Drug Target Screening through Protein Interaction Profiles.Effects of chlorophenoxy herbicides and their main transformation products on DNA damage and acetylcholinesterase activity.Recent advances on A₃ adenosine receptor antagonists by QSAR tools.Discovery of MAO-B inhibitors - present status and future directions part I: oxygen heterocycles and analogs.Desirability-based multi-objective QSAR in drug discovery.Alzheimer's disease, cholesterol, and statins: the junctions of important metabolic pathways.Alzheimer's disease and antioxidant therapy: how long how far?
P50
Q27304699-AA0D1A4F-3586-4FF5-851A-5F7C9906E7FFQ28288818-4853EFCF-8456-4188-82F0-431A6AC8E784Q28289477-90CAF72B-F332-422F-9D7C-057ECDCEDF80Q28302075-554BF068-0E77-4F8F-A6E5-79C34551F32AQ30371299-D51E196F-EF76-49F1-A967-C9FBC5A20577Q30732296-04356742-C3D9-4BA5-BE33-E23FAEBFFCE3Q33318695-5C2DCE96-E33D-4A52-B49E-6C7B4815334AQ33331417-74C3CE0F-10C6-4887-A4DC-0AAEA5E6EFFDQ33376002-F285DC22-4D0D-4525-A772-55383FDC35D0Q33561114-7E580BB8-D1C7-4117-81C6-8713B7576176Q34203570-54F348A1-4479-4543-A5D3-D0F46DBEA7B9Q34325783-2B1CE813-FD3F-4BA3-9F6A-F0B04CFB4B20Q34405635-70F29F60-1396-4702-8E71-4B4BED3C5F96Q34573773-9EB859CA-ED0C-498E-89E0-D8A9DF4FCD45Q34650852-69941651-C809-4F4B-96E9-1B88C8DE785CQ35093314-C825E4A2-7916-469D-8F24-DAE15591875DQ35570593-DB2A81A9-F073-4C9C-B29D-B3BF9256BCA1Q35615350-1B011326-5947-4CDA-88E7-5031E05E3C5CQ35900174-02F8BEB5-79E2-4C6A-AF7F-8018176765C1Q35972211-00C8977C-DC74-4119-A4E9-D4FDC99E25FBQ36087023-3305AE8A-7417-47E1-A31D-291E598BF047Q36107506-19F2B543-B146-4A44-8EA3-B59208755D73Q36250876-EA4B544B-0DBD-42C4-9C14-2A9CAE94577DQ36280585-37315DE9-79B1-486F-AB9D-9A117704FC5AQ36440500-3DCB1055-B9FE-4F48-97F6-1C5DE7C4502EQ36482626-50D37069-B061-4C1A-B9A2-06149B1E4FF6Q36653213-595198C7-9426-42E8-A97D-D2421A44CFCDQ36989984-42310ADA-8405-4FC7-8C18-24411D77C472Q37006018-3B704DBA-1373-4269-934F-9873640EB607Q37081184-C32C963E-A5FB-4879-B61E-ED075D01DFA2Q37148828-ED2A2E9E-48C6-4736-AFE4-BCCF3BC614D6Q37193291-A03C9D33-EEED-4E46-8E38-9FF637D3720CQ37250097-A3CB08BE-0F2B-433F-802A-AD91B483EEE5Q37414273-8B702271-C25A-40FE-B308-B8498CBD880EQ37700538-22B0DAF7-3CF0-4628-B473-CF12A16289B8Q37986864-1ACB6BB4-5B7F-4373-B3C9-8CFDE247DED5Q37993901-D47E0D02-1BDD-47E6-B82A-83EE719AA46AQ37993902-9F4570E8-A427-436F-B413-20B3327B0C50Q38071004-1E7682CB-7C7F-4251-8D2C-CBF087CA4955Q38081479-E21AF866-35BD-4F8D-952C-CDE1CE26D893
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Fernanda Borges
@ast
Fernanda Borges
@en
Fernanda Borges
@es
Fernanda Borges
@nl
Fernanda Borges
@sl
type
label
Fernanda Borges
@ast
Fernanda Borges
@en
Fernanda Borges
@es
Fernanda Borges
@nl
Fernanda Borges
@sl
prefLabel
Fernanda Borges
@ast
Fernanda Borges
@en
Fernanda Borges
@es
Fernanda Borges
@nl
Fernanda Borges
@sl
P106
P21
P2456
P31
P496
0000-0003-1050-2402